Actively Recruiting
Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
Led by St. Mary's Research Center, Canada · Updated on 2026-04-28
210
Participants Needed
1
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty. The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide. This RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.
CONDITIONS
Official Title
Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults undergoing primary total knee arthroplasty (TKA) or total hip arthroplasty (THA) at St-Mary's Hospital
You will not qualify if you...
- Under 18 years of age
- Known allergy or hypersensitivity to tranexamic acid (TXA)
- Previous thromboembolic disease
- Active cancer except local skin cancer
- Significant kidney disease such as hematuria, dialysis, or kidney transplant
- History of seizures
- Known color vision defects
- Unable or unwilling to use the MyMobility app
- Unable to communicate in French or English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St. Mary's Hospital Center
Montreal, Quebec, Canada, H3T 1M5
Actively Recruiting
Research Team
J
Jennifer Mutch, MDCM, FRCSC
CONTACT
S
Sandhya Baskaran, MBA, M.ED
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here